[go: up one dir, main page]

PE20020453A1 - Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos - Google Patents

Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos

Info

Publication number
PE20020453A1
PE20020453A1 PE2001000955A PE2001000955A PE20020453A1 PE 20020453 A1 PE20020453 A1 PE 20020453A1 PE 2001000955 A PE2001000955 A PE 2001000955A PE 2001000955 A PE2001000955 A PE 2001000955A PE 20020453 A1 PE20020453 A1 PE 20020453A1
Authority
PE
Peru
Prior art keywords
alkyl
inhibitors
phenoxyphenoxy
alkenyl
propyl
Prior art date
Application number
PE2001000955A
Other languages
English (en)
Inventor
Soumya P Sahoo
Hiroo Koyama
Julia K Boueres
Ranjit C Desai
Daniel J Miller
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20020453A1 publication Critical patent/PE20020453A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A ACIDOS BENZOPIRANCARBOXILICOS DE FORMULA I DONDE R1 ES H, OH, ALQUILO C1-C7, ALQUENILO C2-C7, ALQUINILO C2-C7, O-ALQUIL C1-C3, CR11R12; R11 Y R12 SON H, HALOGENO, ALQUILO C1-C5, ALQUENILO C2-C5, ALQUINILO C2-C5; Z ES CH2, C=O; X E Y SON O, S, SO2, SO, CH2; n ES 1-6; R4 ES OAr; R2, R3, R5, R6, R7, R8, R9, 10 SON H, HALOGENO, ALQUILO C1-C7, ALQUENILO C2-C7, ALQUINILO C2-C7, OH, O-ALQUIL C1-C5; SON COMPUESTOS PREFERIDOS 7-(3-(2-PROPIL-4-FENOXIFENOXI)PROPOXI)-CROMANO-2-ACIDO CARBOXILICO; 7-(3-(2-PROPIL-4-FENOXIFENOXI)PROPOXI)-2-PROPILCROMANO-2-ACIDO CARBOXILICO; 7-(4-(2-PROPIL-4-FENOXIFENOXI)BUTOXI)-CROMANO-2-ACIDO CARBOXILICO; ENTRE OTROS; TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS a)UN INHIBIDOR DE REDUCTASA HMGCoA: i)AGONISTAS PPARg ( GLITAZONAS; BIGUANIDAS); ii)INHIBIDORES DE TIROSIN FOSFATASA 1B; iv)INHIBIDORES DE PEPTIDOFOSFATASA COMO LOVASTATINA, SIMVASTATINA, PRAVASTATINA, FLUVASTATINA; b)INSULINA, c)SULFONILUREAS (TOLBUTAMINA, GLIPIZIDA, d)INHIBIDORES DE a-GLUCOSIDASA (ACARBOSA), e)AGENTES REDUCTORES DE COLESTEROL (EZETIMIBE), f)COMPUESTOS ANORECTICOS COMO FENFLURAMINA, FENTERMINA; ENTRE OTROS; g)AGENTES ANTIINFLAMATORIOS. LOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR ACTIVADO POR LOS PROLIFERADORES DE PEROXISOMA PPARg Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DIABETES, HIPERGLUCEMIA, HIPERLIPIDEMIA, HDL BAJA, OBESIDAD, HIPERCOLESTEROLEMIA, HIPERTRIGLICERIDEMIA
PE2001000955A 2000-09-27 2001-09-21 Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos PE20020453A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23570800P 2000-09-27 2000-09-27
US24469700P 2000-10-31 2000-10-31

Publications (1)

Publication Number Publication Date
PE20020453A1 true PE20020453A1 (es) 2002-06-06

Family

ID=26929158

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000955A PE20020453A1 (es) 2000-09-27 2001-09-21 Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos

Country Status (7)

Country Link
US (1) US6645997B2 (es)
EP (1) EP1324995A2 (es)
JP (1) JP2004513090A (es)
AU (2) AU2001292874B2 (es)
CA (1) CA2423141A1 (es)
PE (1) PE20020453A1 (es)
WO (1) WO2002026729A2 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023437A1 (fr) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
ATE295724T1 (de) * 2000-02-02 2005-06-15 Warner Lambert Co Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
CN1582168A (zh) * 2001-01-26 2005-02-16 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与心血管药剂的组合
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20040025890A (ko) * 2001-01-26 2004-03-26 쉐링 코포레이션 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
MXPA03006727A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
SI1353696T1 (sl) 2001-01-26 2007-04-30 Schering Corp Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2003225027A1 (en) * 2002-04-16 2003-11-03 Merck And Co., Inc. Combination therapy using a ppar alpha/gamma agonist
WO2004010948A2 (en) 2002-07-30 2004-02-05 Karykion Inc. Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
US7297715B2 (en) 2002-07-30 2007-11-20 Merck & Co., Inc. PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
KR100492252B1 (ko) * 2002-08-09 2005-05-30 한국화학연구원 이미다졸을 포함하는 이차아민으로 치환된 벤조피란유도체 및 그의 제조방법
JP2006508189A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 自己免疫障害の処置のためのコレステロール吸収インヒビター
US7192970B2 (en) 2002-11-26 2007-03-20 Chipscreen Biosciences, Ltd. Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1608317B1 (en) * 2003-03-25 2012-09-26 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
AU2003249492A1 (en) * 2003-07-24 2005-02-14 Eswaran Krishnan Iyer Oral compositions for treatment of diseases
DE602004010206T2 (de) * 2003-08-13 2008-10-09 Takeda Pharmaceutical Co. Ltd. Dipeptidyl Peptidase Inhibitoren.
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
US7514461B2 (en) 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2007509965A (ja) * 2003-10-29 2007-04-19 タワコル，レイフ Ｈｄｌ及びｈｄｌ−２ｂレベルを高めるための組成物及び方法
US20080058292A1 (en) * 2003-10-29 2008-03-06 Raif Tawakol Method for increasing HDL and HDL-2b levels
CA2559302C (en) 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
US7635779B2 (en) * 2004-10-15 2009-12-22 Council Of Scientific & Industrial Research Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents
CN101421258B (zh) * 2004-10-29 2013-08-21 凯利普西斯公司 作为ppar调节剂的磺酰基取代的双环化合物
AU2005307006B2 (en) * 2004-10-29 2012-05-03 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
WO2007011524A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obsity, metabolic syndrome and polycystic ovary syndrome
JP5027137B2 (ja) 2005-09-14 2012-09-19 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤の投与
WO2007033265A1 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
NZ566797A (en) * 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
US20070161006A1 (en) * 2006-01-10 2007-07-12 Vita Genomics, Inc. Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR20090088854A (ko) * 2006-09-13 2009-08-20 다케다 야쿠힌 고교 가부시키가이샤 2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
KR101934197B1 (ko) * 2017-06-12 2018-12-31 아주대학교산학협력단 PPARα/γ 이중 작용 활성을 갖는 신규 화합물 및 이를 유효성분으로 함유하는 대사질환 예방 또는 치료용 조성물
ES2718000B2 (es) * 2017-12-26 2019-12-20 Univ Valencia Benzopiranos prenilados agonistas de ppar
CN115093389B (zh) * 2022-05-31 2024-10-18 广州医科大学 6-酰胺色满-3-甲酰胺衍生物及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474788A (en) 1981-11-12 1984-10-02 Fisons Plc Anti-SRSA quinoline carboxylic acid derivatives
US4680404A (en) * 1983-01-13 1987-07-14 Pfizer Inc. Benzopyrans
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
AU548450B2 (en) 1983-08-08 1985-12-12 G.D. Searle & Co. Substituted dihydrobenzopyrans
US4778903A (en) * 1983-12-12 1988-10-18 G. D. Searle & Co. Substituted dihydrobenzopyrans
US4565882A (en) 1984-01-06 1986-01-21 G. D. Searle & Co. Substituted dihydrobenzopyran-2-carboxylates
US4885309A (en) 1986-08-01 1989-12-05 Hoffmann-La Roche Inc. Therapeutic treatment of leukotriene-mediated dermal inflammation by topical administration of 3,4-dihydro-2H-1-benzopyran derivatives
US5112856A (en) 1986-08-15 1992-05-12 Hoffmann-La Roche Inc. Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives
US4889871A (en) * 1987-05-29 1989-12-26 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylate derivatives
EP0336068A1 (en) 1988-02-11 1989-10-11 F. Hoffmann-La Roche Ag Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives
US5003090A (en) * 1988-08-23 1991-03-26 Hoffmann-La Roche Inc. Process for the preparation of benzopyrans
US5073562A (en) 1990-05-10 1991-12-17 G. D. Searle & Co. Alkoxy-substituted dihydrobenzopyran-2-carboxylic acids and derivatives thereof
US5124350A (en) 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
US5352690A (en) 1992-07-01 1994-10-04 Eli Lilly And Company 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
US5324743A (en) 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5478857A (en) 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
WO1996006604A2 (en) 1994-08-31 1996-03-07 Eli Lilly And Company Methods for identifying and treating resistant tumors
EP0743064A1 (en) 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
AU748861B2 (en) 1998-08-28 2002-06-13 Biomedicines, Inc. Method of mitigating the adverse effects of interleukin-2
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments

Also Published As

Publication number Publication date
JP2004513090A (ja) 2004-04-30
US20020082292A1 (en) 2002-06-27
CA2423141A1 (en) 2002-04-04
AU9287401A (en) 2002-04-08
US6645997B2 (en) 2003-11-11
WO2002026729A3 (en) 2002-08-15
EP1324995A2 (en) 2003-07-09
WO2002026729A2 (en) 2002-04-04
AU2001292874B2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
PE20020453A1 (es) Derivados del acido benzopirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
PE20030227A1 (es) Agonistas de ppar
PE20020354A1 (es) Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
PE20030099A1 (es) Moduladores de los receptores activados por proliferadores de peroxisomas
PE20020693A1 (es) Agonistas del receptor alfa activado del proliferador de peroxisomas
PE20020540A1 (es) Derivados del acido benzo pirancarboxilico para el tratamiento de la diabetes y los trastornos de lipidos
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
PE20090813A1 (es) Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa
AR037882A1 (es) Cis-imidazolinas
PE20081782A1 (es) Agonistas de adrenoreceptores alfa2c
PE20040087A1 (es) 2-(2,6-diclorofenil)-diarilimidazoles
ES2182485T3 (es) Derivados de aminofenil isosazolina sustituidos utiles como agentes antimicrobianos.
AR016523A1 (es) Compuestos de indol como agentes anti-inflamatorios/analgesicos, composiciones farmaceuticas que los contienen y procedimiento de tratamiento
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
ECSP034563A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos
AR020661A1 (es) Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
PE20020573A1 (es) Derivados glucopiranosiloxibencilbenceno, composiciones farmaceuticas que los comprenden e intermedios de los mismos
PE20011056A1 (es) Acidos ariloxiaceticos para la diabetes y trastornos de los lipidos
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
PE20040672A1 (es) Derivados de fenil o heteroaril amino alcano
AR058760A1 (es) Derivados de aril -isoxasol -4-il- imidazol
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
BR9713261A (pt) Tricìclicos substituìdos
SV1997000026A (es) Composiciones farmaceuticas para el tratamiento de la rinitis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal